SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Statistics

Total Valuation

SpyGlass Pharma has a market cap or net worth of $643.80 million. The enterprise value is $537.94 million.

Market Cap	643.80M
Enterprise Value	537.94M

Important Dates

The last earnings date was Thursday, May 14, 2026, after market close.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

SpyGlass Pharma has 33.43 million shares outstanding. The number of shares has increased by 271.41% in one year.

Current Share Class	33.43M
Shares Outstanding	33.43M
Shares Change (YoY)	+271.41%
Shares Change (QoQ)	+807.79%
Owned by Insiders (%)	4.28%
Owned by Institutions (%)	15.95%
Float	6.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.09
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.67, with a Debt / Equity ratio of 0.01.

Current Ratio	12.67
Quick Ratio	12.57
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -67.71% and return on invested capital (ROIC) is -42.04%.

Return on Equity (ROE)	-67.71%
Return on Assets (ROA)	-37.23%
Return on Invested Capital (ROIC)	-42.04%
Return on Capital Employed (ROCE)	-38.64%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$613,369
Employee Count	65
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	23.37
200-Day Moving Average	n/a
Relative Strength Index (RSI)	30.74
Average Volume (20 Days)	59,181

Short Selling Information

The latest short interest is 884,597, so 2.65% of the outstanding shares have been sold short.

Short Interest	884,597
Short Previous Month	1.04M
Short % of Shares Out	2.65%
Short % of Float	13.66%
Short Ratio (days to cover)	11.80

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-41.45M
Pretax Income	-39.87M
Net Income	-39.87M
EBITDA	-40.84M
EBIT	-41.45M
Earnings Per Share (EPS)	-$17.98

Balance Sheet

The company has $107.44 million in cash and $1.58 million in debt, with a net cash position of $105.85 million or $3.17 per share.

Cash & Cash Equivalents	107.44M
Total Debt	1.58M
Net Cash	105.85M
Net Cash Per Share	$3.17
Equity (Book Value)	105.70M
Book Value Per Share	-44.85
Working Capital	100.18M

Cash Flow

Operating Cash Flow	-32.70M
Capital Expenditures	-789,000
Depreciation & Amortization	697,250
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SpyGlass Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-271.41%
Shareholder Yield	-271.41%
Earnings Yield	-6.19%
FCF Yield	n/a

Analyst Forecast

The average price target for SpyGlass Pharma is $45.00, which is 133.65% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$45.00
Price Target Difference	133.65%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2